Menu Search
Equities

Fuji Pharma Co Ltd

4554:TYO

Fuji Pharma Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,374.00
  • Today's Change33.00 / 2.46%
  • Shares traded131.10k
  • 1 Year change-4.72%
  • Beta0.7476
Data delayed at least 20 minutes, as of Nov 14 2024 05:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Fuji Pharma Co Ltd grew revenues 12.84% from 40.89bn to 46.14bn while net income improved 78.87% from 3.44bn to 6.15bn.
Gross margin39.28%
Net profit margin14.28%
Operating margin11.75%
Return on assets7.36%
Return on equity14.90%
Return on investment11.63%
More ▼

Cash flow in JPYView more

In 2024, Fuji Pharma Co Ltd increased its cash reserves by 97.29%, or 2.26bn. The company earned 4.15bn from its operations for a Cash Flow Margin of 9.00%. In addition the company used 1.66bn on investing activities and also paid 435.00m in financing cash flows.
Cash flow per share405.15
Price/Cash flow per share3.33
Book value per share1,849.15
Tangible book value per share1,415.66
More ▼

Balance sheet in JPYView more

Fuji Pharma Co Ltd has a Debt to Total Capital ratio of 39.12%, a higher figure than the previous year's 30.76%.
Current ratio1.21
Quick ratio0.6276
Total debt/total equity0.6426
Total debt/total capital0.3912
More ▼

Growth rates in JPY

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 5.71% and 27.37%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)2.68%
Div growth rate (5 year)5.73%
Payout ratio (TTM)15.28%
EPS growth(5 years)4.64
EPS (TTM) vs
TTM 1 year ago		212.43
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.